Conveners
Research on targeted radionuclide therapy and associated technologies
- Cornelia Hoehr (Life Sciences, TRIUMF Canadian Particle Accelerator and University of Victoria, Canada)
The cyclotron-based production of radionuclides for medicine is one of the research activities carried out in the framework of the SPES (Selective Production of Exotic Species) project at the Legnaro National Laboratories of the National Institute for Nuclear Physics (INFN-LNL). SPES aims at the construction of an advanced ISOL (Isotope Separation On-Line) facility to produce re-accelerated...
Using unconventional radionuclides for cancer treatment has been gaining popularity in recent years thanks to the remarkable results from the clinical studies with 177Lu, 223Ra and 225Ac1–3. TRIUMF launched a campaign to produce 225Ac from 232Th spallation4. Benefiting from this program, several other interesting alpha-emitters are co-produced, including 213Bi, 227Th, and 212Pb, which we have...